<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02807389</url>
  </required_header>
  <id_info>
    <org_study_id>15-004326</org_study_id>
    <nct_id>NCT02807389</nct_id>
  </id_info>
  <brief_title>Stem Cell Fistula Plug in Post Surgical Leak Fistulas</brief_title>
  <official_title>A Phase I Study of Autologous Mesenchymal Stromal Cell Coated Fistula Plug in Patients With Complicated Post-surgical Fistulas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to study the safety of autologous mesenchymal stromal cell transfer&#xD;
      using a biomatrix (The Gore Fistula Plug) in a Phase I study using a single dose of 20&#xD;
      million cells. 15 adult patients (age 18 and greater) with persistent symptomatic&#xD;
      post-surgical gastrointestinal leaks despite current standard radiologic and endoscopic&#xD;
      therapies will be enrolled. The subjects will be subsequently followed for fistula response&#xD;
      and closure for 18 months. This is an autologous product derived from the patient and used&#xD;
      only for the same patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Visit 1: Patients will be evaluated for eligibility (inclusion/exclusion checklist) and&#xD;
      written, informed consent will be obtained. Patients will undergo general exam with vital&#xD;
      signs. Patients will be scheduled for a fat biopsy to collect the tissue needed to grow MSC.&#xD;
      In the event there is no cell growth from the tissue obtained from the first biopsy, one&#xD;
      further attempt will made from a second tissue sample from this patient. However, if the&#xD;
      second attempt fails to grow cells, no further attempts will be made, and the subject will&#xD;
      not continue in the study.&#xD;
&#xD;
      Visit 2 (Week 0; Day 0): Patients will undergo an interventional endoscopy, the fistula tract&#xD;
      will be assessed and the stem cell coated will be placed endoscopically.&#xD;
&#xD;
      Study visit will be as follows:&#xD;
&#xD;
      Visit 3 (Week 0; Day 1) Visit 4 (Week 2; Month 1) Visit 5 (Week 4; Month 1) Visit 6 (Week 8;&#xD;
      Month 2) Visit 7 (Week 12; Month 3) Visit 8 (Week 24; Month 6) Visit 9 (week 52; Month 12)&#xD;
      Visit 10 (Week 78; Month 18)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 14, 2017</start_date>
  <completion_date type="Actual">April 2, 2019</completion_date>
  <primary_completion_date type="Actual">April 2, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>2-18 months</time_frame>
    <description>Data collection will include: worsening of the fistula, abnormal laboratory values, or significant abnormalities in physical examination. The Outcome Measure will be the number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Fistula Closure</measure>
    <time_frame>2-18 months</time_frame>
    <description>Data collection will include: degree of drainage cessation from fistula. The Outcome Measure will be the number of Participants With Closure of their Fistula.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Surgical Leak Fistula</condition>
  <arm_group>
    <arm_group_label>MSC Fistula plug: Single Treatment Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received treatment of a stem cell coated fistula plug.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MSC Fistula Plug</intervention_name>
    <description>Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.</description>
    <arm_group_label>MSC Fistula plug: Single Treatment Group</arm_group_label>
    <other_name>mesenchymal stromal cell coated fistula plug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Males and females 18-75 years of age.&#xD;
&#xD;
          2. Residents of the United States.&#xD;
&#xD;
          3. Patients with persistent symptomatic fistulas arising after gastro-esophageal&#xD;
             resections, enteric or colonic resections or Bariatric surgeries.&#xD;
&#xD;
          4. Single-tract fistula&#xD;
&#xD;
          5. Have no contraindications to imaging evaluations: e.g. contrast allergies&#xD;
&#xD;
          6. Ability to comply with protocol&#xD;
&#xD;
          7. Competent and able to provide written informed consent&#xD;
&#xD;
          8. Must have failed standard conservative therapy which includes at least one endoscopic&#xD;
             attempt to resolve fistula. Standard conservative management includes drainage of&#xD;
             sepsis, antibiotics, nutritional support, etc. Endoscopic closure attempt with devices&#xD;
             such as, but not limited to; endo-stitch, clipping, surgical sealants, etc. This&#xD;
             attempt may be with or without diversion of the luminal contents by stenting.&#xD;
&#xD;
          9. Radiographic Imaging within 7 days of fistula plug placement (e.g. CT, PET, etc.).&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          1. Inability to give informed consent.&#xD;
&#xD;
          2. Clinically significant medical conditions within the six months before administration&#xD;
             of MSCs: e.g. myocardial infarction, active angina, congestive heart failure or other&#xD;
             conditions that would, in the opinion of the investigators, compromise the safety of&#xD;
             the patient.&#xD;
&#xD;
          3. Specific exclusions;&#xD;
&#xD;
             a. Evidence of hepatitis B, C, or HIV&#xD;
&#xD;
          4. Investigational drug within thirty (30) days of baseline&#xD;
&#xD;
          5. A resident outside the United States&#xD;
&#xD;
          6. History of clinically significant auto-immunity (i.e. Inflammatory Bowel Disease).&#xD;
&#xD;
          7. Previous allergic reaction to a fistula plug.&#xD;
&#xD;
          8. If obtaining sufficient adipose tissue for manufacturing is not technically feasible&#xD;
&#xD;
          9. Allergic to local anesthetics&#xD;
&#xD;
         10. Pregnant patients or trying to become pregnant or breast feeding.&#xD;
&#xD;
         11. Non-enterocutaneous tracts&#xD;
&#xD;
         12. Fistula output &gt;2000 ml/day&#xD;
&#xD;
         13. Multiple or end fistulas&#xD;
&#xD;
         14. Fistulous tract &lt;2 cm in length&#xD;
&#xD;
         15. Fistulous tract or defect &gt;1 cm in diameter,&#xD;
&#xD;
         16. Fistulas opening into abdominal wall defect.&#xD;
&#xD;
         17. Diseased adjacent bowel, fistula in the radiation field, persistent distal obstruction&#xD;
             or malignancy&#xD;
&#xD;
         18. Patients on immunosuppression or chemotherapy&#xD;
&#xD;
         19. Uncontrolled diabetes, i.e. blood sugar more than 200&#xD;
&#xD;
         20. Sepsis&#xD;
&#xD;
         21. Fistulas arising from a malignant lesion&#xD;
&#xD;
         22. Patients with obstructive malignancies&#xD;
&#xD;
         23. Patients with stage III and/or stage IV cancers. The investigators will exclude&#xD;
             patients with stage III or IV cancers, poorly differentiated cancers and patients with&#xD;
             less than accepted disease free surgical margins.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William A Faubion, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic in Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mayo.edu/research/clinical-trials</url>
    <description>Mayo Clinic Clinical Trials</description>
  </link>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 15, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 21, 2016</study_first_posted>
  <last_update_submitted>April 19, 2019</last_update_submitted>
  <last_update_submitted_qc>April 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>William A. Faubion, M.D.</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

